Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | MLYCD | O95822 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | ITK | Q08881 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27597814 | 0.81 | NCF1 (0.52) | NCF1SMN1; SMN2MAPTLMNAHSD17B10 | |
| SCHEMBL5022762 | 0.81 | SMN1; SMN2 (0.64) | ALDH1A1SMN1; SMN2NPC1RAB9AL3MBTL1 | |
| SCHEMBL5022742 | 0.78 | NCF1 (0.48) | NCF1ALDH1A1SMN1; SMN2HSD17B10KDM4E | |
| SCHEMBL27597796 | 0.77 | NCF1 (0.49) | NCF1ALDH1A1SMN1; SMN2L3MBTL1MAPT | |
| SCHEMBL27597792 | 0.74 | NCF1 (0.53) | NCF1SMN1; SMN2MAPTLMNAHSD17B10 | |
| SCHEMBL5416659 | 0.74 | NCF1 (0.56) | NCF1ALDH1A1SMN1; SMN2L3MBTL1MAPT | |
| SCHEMBL5025361 | 0.74 | NCF1 (0.53) | NCF1ALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL5412427 | 0.73 | NCF1 (0.59) | NCF1ALDH1A1SMN1; SMN2L3MBTL1MAPT | |
| SCHEMBL5028584 | 0.73 | NCF1 (0.65) | NCF1SMN1; SMN2L3MBTL1MAPTLMNA | |
| SCHEMBL5518457 | 0.71 | NCF1 (0.62) | NCF1L3MBTL1MAPTLMNAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1474145-B1 | QUINOLINE DERIVATIVES AS NPY ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2008-04-23 | — | — | EP | claimed |
| CN-1627945-A | Quinoline derivatives as NPY antagonists | HOFFMANN LA ROCHE (CH) | 2005-06-15 | — | — | CN | claimed |
| EP-1474145-A1 | QUINOLINE DERIVATIVES AS NPY ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-10 | — | — | EP | claimed |
| US-6696467-B2 | Quinoline derivatives | HOFFMANN-LA ROCHE INC. | 2004-02-24 | — | — | US | claimed |
| US-20030153553-A1 | Quinoline derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2003-08-14 | — | — | US | claimed |
| WO-2003066055-A1 | QUINOLINE DERIVATIVES AS NPY ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-08-14 | — | — | WO | claimed |
| EP-1474145-B1 | QUINOLINE DERIVATIVES AS NPY ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2008-04-23 | — | — | EP | disclosed |
| CN-1627945-A | Quinoline derivatives as NPY antagonists | HOFFMANN LA ROCHE (CH) | 2005-06-15 | — | — | CN | disclosed |
| EP-1474145-A1 | QUINOLINE DERIVATIVES AS NPY ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-10 | — | — | EP | disclosed |
| US-6696467-B2 | Quinoline derivatives | HOFFMANN-LA ROCHE INC. | 2004-02-24 | — | — | US | disclosed |
| US-20030153553-A1 | Quinoline derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2003-08-14 | — | — | US | disclosed |
| WO-2003066055-A1 | QUINOLINE DERIVATIVES AS NPY ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153553-A1 | Quinoline derivatives | NPY1R, NPY4R, GLP1R | NCF1 1858/4885ALDH1A1 1477/4885SMN1; SMN2 2329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.